NASDAQ:AKBA - Akebia Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.54 +0.15 (+1.79 %) (As of 03/25/2019 03:00 PM ET)Previous Close$8.39Today's Range$8.35 - $8.6452-Week Range$5.20 - $11.60Volume31,209 shsAverage Volume1.64 million shsMarket Capitalization$487.29 millionP/E Ratio-4.82Dividend YieldN/ABeta1.46 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Receive AKBA News and Ratings via Email Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA Previous Symbol CUSIPN/A CIK1517022 Webwww.akebia.com Phone617-871-2098Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio2.24Price-To-Earnings Trailing P/E Ratio-4.82 Forward P/E Ratio-4.82 P/E GrowthN/A Sales & Book Value Annual Sales$177.98 million Price / Sales2.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.52 per share Price / Book3.39Profitability EPS (Most Recent Fiscal Year)($1.77) Net Income$-76,910,000.00 Net Margins-30.29% Return on Equity-45.61% Return on Assets-17.54%Miscellaneous Employees113 Outstanding Shares57,060,000Market Cap$487.29 million Next Earnings DateN/A OptionableOptionable Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics Inc (NASDAQ:AKBA) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.18. The biopharmaceutical company earned $53.17 million during the quarter, compared to analysts' expectations of $39.71 million. Akebia Therapeutics had a negative net margin of 30.29% and a negative return on equity of 45.61%. View Akebia Therapeutics' Earnings History. What price target have analysts set for AKBA? 6 brokers have issued 12 month price objectives for Akebia Therapeutics' shares. Their predictions range from $9.00 to $22.00. On average, they expect Akebia Therapeutics' stock price to reach $15.1429 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics. What is the consensus analysts' recommendation for Akebia Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics. What are Wall Street analysts saying about Akebia Therapeutics stock? Here are some recent quotes from research analysts about Akebia Therapeutics stock: 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/1/2019) 2. Mizuho analysts commented, "We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat." (12/4/2018) Has Akebia Therapeutics been receiving favorable news coverage? News headlines about AKBA stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akebia Therapeutics earned a news impact score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the next few days. Who are some of Akebia Therapeutics' key competitors? Some companies that are related to Akebia Therapeutics include Heron Therapeutics (HRTX), Endo International (ENDP), Supernus Pharmaceuticals (SUPN), Enanta Pharmaceuticals (ENTA), Mallinckrodt (MNK), Zai Lab (ZLAB), Xencor (XNCR), Arrowhead Pharmaceuticals (ARWR), Myovant Sciences (MYOV), Pacira Pharmaceuticals (PCRX), Allakos (ALLK), Opko Health (OPK), Puma Biotechnology (PBYI), Prestige Consumer Healthcare (PBH) and Wave Life Sciences (WVE). What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Gilead Sciences (GILD), FireEye (FEYE), Synergy Pharmaceuticals (SGYP), Energy Transfer LP Unit (ET), AT&T (T), TherapeuticsMD (TXMD), Micron Technology (MU) and Netflix (NFLX). Who are Akebia Therapeutics' key executives? Akebia Therapeutics' management team includes the folowing people: Mr. John P. Butler, CEO, Pres & Director (Age 55)Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 40)Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)Ms. Nicole R. Hadas, Sr. VP, Gen. Counsel & Sec. (Age 46) Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Baupost Group LLC MA (42.89%), BlackRock Inc. (14.54%), Perceptive Advisors LLC (2.99%), Northern Trust Corp (1.87%), Geode Capital Management LLC (1.77%) and Geode Capital Management LLC (1.77%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics. Which major investors are selling Akebia Therapeutics stock? AKBA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, First Manhattan Co., FMR LLC, Tekla Capital Management LLC, Millennium Management LLC, Tocqueville Asset Management L.P., Virtus ETF Advisers LLC and Bank of America Corp DE. View Insider Buying and Selling for Akebia Therapeutics. Which major investors are buying Akebia Therapeutics stock? AKBA stock was acquired by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, BlackRock Inc., Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Old West Investment Management LLC, Northern Trust Corp and Geode Capital Management LLC. View Insider Buying and Selling for Akebia Therapeutics. How do I buy shares of Akebia Therapeutics? Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $8.54. How big of a company is Akebia Therapeutics? Akebia Therapeutics has a market capitalization of $487.29 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 113 workers across the globe. What is Akebia Therapeutics' official website? The official website for Akebia Therapeutics is http://www.akebia.com. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected] MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 508MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Equity (ROE)?